The Top Line How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)
7 snips
Feb 3, 2026 Ajay Narasimha, Mirum Pharmaceuticals SVP of corporate strategy and business development and scientist-turned-commercial exec, discusses Mirum’s first acquisition of Bluejay and why brelovitug targets a critical unmet need in hepatitis delta virus. He outlines how the deal fits Mirum’s rare liver disease strategy, upcoming registrational readouts, and the company’s approach to patient-centric dealmaking and pipeline building.
AI Snips
Chapters
Transcript
Episode notes
Targeting Unmet Need In Hepatitis Delta
- Mirum acquired Bluejay to address hepatitis delta, a severe, underserved rare liver disease with no FDA-approved treatments.
- Ajay Narasimha says brelovitug is a transformative monoclonal antibody that blocks HDV replication by targeting HB surface antigen.
Acquire Where You Add Commercial Value
- Mirum leverages its late-stage development, regulatory, and commercial infrastructure when acquiring assets post-phase 2.
- Ajay recommends partnering where the acquirer can add clear commercialization and regulatory value.
Pipeline Built By Smart Acquisitions
- Mirum's business model focuses on in-licensing or acquiring underappreciated rare-disease assets rather than internal R&D.
- Ajay says these assets become the company's lifeblood, developed by Mirum's proven operators.